Schistosomiasis

From 2000 to 2017 the Sabin Vaccine Institute partnered with the Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas to develop safe, effective and low-cost vaccines for infectious and neglected tropical diseases. Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development continue this research as of May 2017.

Past Work

For more than a decade, the Sabin PDP collaborated with partners from across the globe to develop new, low-cost vaccines that have little commercial market for diseases that primarily impact the world's poorest populations, including human hookworm, schistosomiasis, onchocerciasis, SARS and Chagas disease. Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development continue this research as of May 2017.

Research & Development

The Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health.  Sabin leverages the expertise of partners in the academic, public and private sectors, and promotes open-source research.

Dr. Jan Holmgren Receives 2017 Albert B. Sabin Gold Medal Award

WASHINGTON, D.C. – April 25, 2017 – Tonight, the Sabin Vaccine Institute (Sabin) will honor Dr. Jan Holmgren with the 2017 Albert B. Sabin Gold Medal Award. Dr. Holmgren will be recognized for his pioneering contributions to oral vaccine research and mucosal immunology, as well as his leadership in the discovery of the world's first effective oral cholera vaccine.

While investments in biomedical R&D have led to tremendous scientific breakthroughs and health improvements in the modern era, the benefits have been shared unevenly.

An estimated two billion people lack the medicines they need. The 2016 Access to Medicines Index analyzes pharmaceutical companies’ efforts to improve access to medicines, vaccines and diagnostics for low- and middle-income countries.

More than two billion people lack access to necessary medicines. High costs and limited health care infrastructure prevent many people from benefiting from recent medical advancements, leaving populations at risk of preventable diseases.

Sabin Vaccine Institute Joins Coalition Dedicated to Preventing Future Epidemics

Geneva, Switzerland – November 18, 2016 – Today, the Sabin Vaccine Institute (Sabin) begins its formal membership with the Coalition for Epidemic Preparedness Innovations (CEPI), as global health leaders gather in Geneva, Switzerland for the first meeting of CEPI’s Joint Coordination Group (JCG).

Pages

Subscribe to RSS - Research & Development